Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
{
"resourceType" : "Group",
"id" : "7750",
"meta" : {
"versionId" : "8",
"lastUpdated" : "2023-12-05T12:59:21.649Z"
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: Group</b><a name=\"7750\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource Group "7750" Version "8" Updated "2023-12-05 12:59:21+0000" </p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact URL</b>: <a href=\"https://fevir.net/resources/Group/7750\">https://fevir.net/resources/Group/7750</a></p><p><b>Artifact Date</b>: 2022-01-11 17:20:56+0000</p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: all-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier:\u00a07750</p><p><b>type</b>: person</p><p><b>membership</b>: enumerated</p><p><b>name</b>: Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill</p><p><b>description</b>: An enumerated group participating in a randomized trial.</p><p><b>quantity</b>: 2244</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT</p><p><b>code</b>: Research Study for which this is the observed sample <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><p><b>value</b>: <a href=\"Citation-7636.html\">Citation/7636: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.</a></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Hospitalized</p><p><b>code</b>: Admission to establishment (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#305335007)</span></p><p><b>value</b>: Hospital admission <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#32485007)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: COVID-19</p><p><b>code</b>: Disease (disorder) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#64572001)</span></p><p><b>value</b>: ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#840539006 "Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)")</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: not critically ill</p><p><b>code</b>: Severity <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#246112005)</span></p><p><b>value</b>: severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#442452003 "Life threatening severity")</span></p><p><b>exclude</b>: true</p></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
"valueRelatedArtifact" : {
"type" : "cite-as",
"citation" : "Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750."
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-url",
"valueUri" : "https://fevir.net/resources/Group/7750"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-date",
"valueDateTime" : "2022-01-11T17:20:56.687Z"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-publisher",
"valueString" : "Computable Publishing LLC"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-copyright",
"valueMarkdown" : "https://creativecommons.org/licenses/by-nc-sa/4.0/"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-contact",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Brian S. Alper"
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method",
"valueCode" : "all-of"
}
],
"modifierExtension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-status",
"valueCode" : "active"
}
],
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "7750",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"type" : "person",
"membership" : "enumerated",
"name" : "Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill",
"description" : "An enumerated group participating in a randomized trial.",
"quantity" : 2244,
"characteristic" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT"
}
],
"code" : {
"text" : "Research Study for which this is the observed sample"
},
"valueReference" : {
🔗 "reference" : "Citation/7636",
"display" : "Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911."
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "Hospitalized"
}
],
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "305335007",
"display" : "Admission to establishment (procedure)"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "32485007",
"display" : "Hospital admission"
}
]
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "COVID-19"
}
],
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "64572001",
"display" : "Disease (disorder)"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "840539006",
"display" : "Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)"
}
],
"text" : "ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19."
},
"exclude" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description",
"valueMarkdown" : "not critically ill"
}
],
"code" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "246112005",
"display" : "Severity"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "442452003",
"display" : "Life threatening severity"
}
],
"text" : "severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)"
},
"exclude" : true
}
]
}
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change